New cell-based assay for reliable testing of HIV inhibitors

NewsGuard 100/100 Score

EASY-HIT is a new cell-based assay system for simple and reliable testing of HIV inhibitors. This system was developed under the leadership of Professor Ruth Brack-Werner at the Institute of Virology. At the heart of the system are cultured human cells that allow HIV to enter and replicate efficiently and that signal HIV infection by producing a red fluorescent protein. The EASY-HIT technology can be used to identify HIV-inhibitors, measure the potency of their inhibitory activity and to detect the stage of replication targeted by the inhibitor.

The researchers validated their technology with a panel of currently used anti-HIV drugs and then went on to identify 5 new HIV inhibitors. They also showed that this technology can be used to detect anti-HIV activities in raw plant extracts. The researchers are currently using this system to explore numerous biological specimens for anti-HIV activities and have already discovered novel unexpected sources of antiviral activities.

Stephan Kremb, first author of the manuscript, summarizes, "We expect the versatile and robust EASY-HIT system to identify new targets against HIV and new sources of HIV-inhibitors". "Our technology has many applications in HIV research and pharmaceutical drug design", adds Ruth Brack-Werner.

HIV was first discovered in the early 1980s and described as the causative agent of AIDS. As there is no cure for HIV infection as yet, HIV-infected individuals require life-long treatment with antiviral drugs. The problems with currently available therapies include drug side-effects, the emergence of resistant viruses and the cost of long-term treatment. "It is our particularly hope that the EASY-HIT technology will promote the development of new strategies for HIV treatment in areas with limited resources", states Ruth Brack-Werner.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Discovery of new vascular cell type may pave way for novel strategies to treat cardiovascular diseases